SCHEMBL20715480

SCHEMBL20715480

CC(C)Cc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.60
HDAC1 Q13547 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
TRPV1 Q8NER1 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
MAPT P10636 3/20 0.56
HTT P42858 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NLRP1 Q9C000 1/20 0.56
CNR1 P21554 3/20 0.55
GAA P10253 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
EPHX2 P34913 2/20 0.51
LMNA P02545 2/20 0.51
NLRP3 Q96P20 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20715666 0.86 SMN1; SMN2 (0.59) TRPV1ALDH1A1MEN1KMT2ANPC1
SCHEMBL20715474 0.85 SMN1; SMN2 (0.59) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL20715659 0.83 RAB9A (0.54) FPR2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL10160141 0.83 SMN1; SMN2 (0.55) FPR2ALDH1A1MEN1KMT2ANPC1
SCHEMBL1759809 0.82 CNR1 (0.54) FPR2HDAC1HDAC6ALDH1A1MEN1
SCHEMBL23634207 0.81 CA12 (0.55) FPR2MEN1KMT2ARAB9AMAPT
SCHEMBL4121749 0.81 RAB9A (0.67) HDAC1HDAC6ALDH1A1MEN1KMT2A
SCHEMBL20715710 0.81 SMN1; SMN2 (0.50) FPR2TRPV1NPC1RAB9AMAPT
SCHEMBL20715707 0.81 SAE1 (0.71) FPR2MEN1KMT2ANPC1RAB9A
SCHEMBL21501999 0.80 MAPT (0.52) NPC1RAB9AMAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 US disclosed
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2019-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 FPR2 731/4885HDAC1 2559/4885HDAC6 2200/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 FPR2 736/4885HDAC1 2556/4885HDAC6 2173/4885
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 FPR2 731/4885HDAC1 2559/4885HDAC6 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.